Comparative Pharmacology
Head-to-head clinical analysis: AVANDAMET versus KOMBIGLYZE XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDAMET versus KOMBIGLYZE XR.
AVANDAMET vs KOMBIGLYZE XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVANDAMET combines rosiglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Oral, initial dose of rosiglitazone 4 mg/metformin 500 mg twice daily or rosiglitazone 2 mg/metformin 500 mg twice daily; maximum recommended dose rosiglitazone 8 mg/metformin 2000 mg per day.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
None Documented
None Documented
Rosiglitazone: 3-4 hours (terminal); metformin: 6.2 hours (terminal). No accumulation with normal renal function.
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Renal (90-95% as unchanged drug for rosiglitazone; metformin is 90% renally eliminated unchanged). Biliary/fecal: minor (<5% for both).
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Category C
Category C
Thiazolidinedione and Biguanide Combination
DPP-4 Inhibitor + Biguanide Combination